drugset / Trial / NCT00747968
The Effect of the GLP-1 Analogue Exenatide on Type 2 Diabetes in CNS and Heart During Hyperglycemia Assessed by PET
Phase 2/3
Completed
8 enrolled
University of Aarhus
Aarhus University Hospital · collabEli Lilly and Company · collab
RandomizedCrossoverTriple-blindBasic science
Summary
30 type 2 diabetic patients will be PET-scanned twice ( half of the patients heart-PET, half of the patients CNS-PET) in random order with infusions of placebo or GLP-1-analogue during hyperglycemic clamp to uncover the metabolic effects of GLP-1-analogues in perspectives of intervention of macrovascular late diabetic pathology such as stroke and AMI. Earlier studies have revealed tendencies towards steady glucose metabolism in the CNS despite fluctuations in blood sugar when infusing native GLP-1.
Timeline
- Start
- 2010-02
- Primary completion
- 2010-11
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Exenatide | Peptide | 0.066 unknown | Other |